nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylphenidate—Warmth—Liotrix—hypothyroidism	0.025	0.0277	CcSEcCtD
Methylphenidate—Serum sickness—Dextrothyroxine—hypothyroidism	0.0231	0.0256	CcSEcCtD
Methylphenidate—Serum sickness—Levothyroxine—hypothyroidism	0.0231	0.0256	CcSEcCtD
Methylphenidate—Muscle twitching—Liothyronine—hypothyroidism	0.0224	0.0248	CcSEcCtD
Methylphenidate—Serum sickness—Liotrix—hypothyroidism	0.017	0.0188	CcSEcCtD
Methylphenidate—Angina pectoris—Liothyronine—hypothyroidism	0.0135	0.0149	CcSEcCtD
Methylphenidate—Acute coronary syndrome—Liothyronine—hypothyroidism	0.0122	0.0135	CcSEcCtD
Methylphenidate—Myocardial infarction—Liothyronine—hypothyroidism	0.0121	0.0134	CcSEcCtD
Methylphenidate—Feeling hot—Liotrix—hypothyroidism	0.0101	0.0112	CcSEcCtD
Methylphenidate—Abscess—Liotrix—hypothyroidism	0.0101	0.0111	CcSEcCtD
Methylphenidate—Coma—Dextrothyroxine—hypothyroidism	0.00989	0.0109	CcSEcCtD
Methylphenidate—Coma—Levothyroxine—hypothyroidism	0.00989	0.0109	CcSEcCtD
Methylphenidate—Arrhythmia—Liothyronine—hypothyroidism	0.00989	0.0109	CcSEcCtD
Methylphenidate—Hyperkinesia—Levothyroxine—hypothyroidism	0.00944	0.0105	CcSEcCtD
Methylphenidate—Hyperkinesia—Dextrothyroxine—hypothyroidism	0.00944	0.0105	CcSEcCtD
Methylphenidate—SLC6A4—Monoamine Transport—SLC5A7—hypothyroidism	0.00934	0.107	CbGpPWpGaD
Methylphenidate—Disorientation—Dextrothyroxine—hypothyroidism	0.00878	0.00972	CcSEcCtD
Methylphenidate—Disorientation—Levothyroxine—hypothyroidism	0.00878	0.00972	CcSEcCtD
Methylphenidate—SLC6A2—Amine compound SLC transporters—SLC5A7—hypothyroidism	0.00846	0.0969	CbGpPWpGaD
Methylphenidate—Ulcer—Liotrix—hypothyroidism	0.00842	0.00932	CcSEcCtD
Methylphenidate—Increased appetite—Levothyroxine—hypothyroidism	0.00836	0.00926	CcSEcCtD
Methylphenidate—Increased appetite—Dextrothyroxine—hypothyroidism	0.00836	0.00926	CcSEcCtD
Methylphenidate—Hypertension—Liothyronine—hypothyroidism	0.00832	0.00921	CcSEcCtD
Methylphenidate—Muscle twitching—Liotrix—hypothyroidism	0.00811	0.00898	CcSEcCtD
Methylphenidate—Hypoglycaemia—Dextrothyroxine—hypothyroidism	0.00805	0.00891	CcSEcCtD
Methylphenidate—Hypoglycaemia—Levothyroxine—hypothyroidism	0.00805	0.00891	CcSEcCtD
Methylphenidate—SLC6A2—Monoamine Transport—SLC5A7—hypothyroidism	0.00803	0.092	CbGpPWpGaD
Methylphenidate—Affect lability—Levothyroxine—hypothyroidism	0.00774	0.00856	CcSEcCtD
Methylphenidate—Affect lability—Dextrothyroxine—hypothyroidism	0.00774	0.00856	CcSEcCtD
Methylphenidate—Tachycardia—Liothyronine—hypothyroidism	0.00768	0.0085	CcSEcCtD
Methylphenidate—Irritability—Levothyroxine—hypothyroidism	0.0075	0.0083	CcSEcCtD
Methylphenidate—Irritability—Dextrothyroxine—hypothyroidism	0.0075	0.0083	CcSEcCtD
Methylphenidate—SLC6A3—Amine compound SLC transporters—SLC5A7—hypothyroidism	0.0075	0.0858	CbGpPWpGaD
Methylphenidate—Cardiac arrest—Levothyroxine—hypothyroidism	0.00747	0.00827	CcSEcCtD
Methylphenidate—Cardiac arrest—Dextrothyroxine—hypothyroidism	0.00747	0.00827	CcSEcCtD
Methylphenidate—Mood swings—Dextrothyroxine—hypothyroidism	0.00744	0.00824	CcSEcCtD
Methylphenidate—Mood swings—Levothyroxine—hypothyroidism	0.00744	0.00824	CcSEcCtD
Methylphenidate—Dehydration—Dextrothyroxine—hypothyroidism	0.00731	0.00809	CcSEcCtD
Methylphenidate—Dehydration—Levothyroxine—hypothyroidism	0.00731	0.00809	CcSEcCtD
Methylphenidate—Coma—Liotrix—hypothyroidism	0.00728	0.00805	CcSEcCtD
Methylphenidate—SLC6A3—Monoamine Transport—SLC5A7—hypothyroidism	0.00712	0.0815	CbGpPWpGaD
Methylphenidate—Hyperkinesia—Liotrix—hypothyroidism	0.00695	0.00769	CcSEcCtD
Methylphenidate—Angina pectoris—Dextrothyroxine—hypothyroidism	0.00662	0.00732	CcSEcCtD
Methylphenidate—Angina pectoris—Levothyroxine—hypothyroidism	0.00662	0.00732	CcSEcCtD
Methylphenidate—Swelling—Liotrix—hypothyroidism	0.00655	0.00725	CcSEcCtD
Methylphenidate—Disorientation—Liotrix—hypothyroidism	0.00646	0.00715	CcSEcCtD
Methylphenidate—Body temperature increased—Liothyronine—hypothyroidism	0.00622	0.00688	CcSEcCtD
Methylphenidate—Increased appetite—Liotrix—hypothyroidism	0.00615	0.00681	CcSEcCtD
Methylphenidate—Weight decreased—Dextrothyroxine—hypothyroidism	0.00614	0.0068	CcSEcCtD
Methylphenidate—Weight decreased—Levothyroxine—hypothyroidism	0.00614	0.0068	CcSEcCtD
Methylphenidate—Acute coronary syndrome—Levothyroxine—hypothyroidism	0.00597	0.00661	CcSEcCtD
Methylphenidate—Acute coronary syndrome—Dextrothyroxine—hypothyroidism	0.00597	0.00661	CcSEcCtD
Methylphenidate—Myocardial infarction—Levothyroxine—hypothyroidism	0.00594	0.00657	CcSEcCtD
Methylphenidate—Myocardial infarction—Dextrothyroxine—hypothyroidism	0.00594	0.00657	CcSEcCtD
Methylphenidate—Hypoglycaemia—Liotrix—hypothyroidism	0.00592	0.00656	CcSEcCtD
Methylphenidate—Cerebrovascular accident—Liotrix—hypothyroidism	0.0059	0.00653	CcSEcCtD
Methylphenidate—Sweating—Dextrothyroxine—hypothyroidism	0.00581	0.00643	CcSEcCtD
Methylphenidate—Sweating—Levothyroxine—hypothyroidism	0.00581	0.00643	CcSEcCtD
Methylphenidate—Affect lability—Liotrix—hypothyroidism	0.00569	0.0063	CcSEcCtD
Methylphenidate—Irritability—Liotrix—hypothyroidism	0.00552	0.00611	CcSEcCtD
Methylphenidate—Cardiac arrest—Liotrix—hypothyroidism	0.0055	0.00608	CcSEcCtD
Methylphenidate—Mood swings—Liotrix—hypothyroidism	0.00548	0.00606	CcSEcCtD
Methylphenidate—Dehydration—Liotrix—hypothyroidism	0.00538	0.00595	CcSEcCtD
Methylphenidate—Flushing—Dextrothyroxine—hypothyroidism	0.00505	0.00558	CcSEcCtD
Methylphenidate—Flushing—Levothyroxine—hypothyroidism	0.00505	0.00558	CcSEcCtD
Methylphenidate—Angina pectoris—Liotrix—hypothyroidism	0.00487	0.00539	CcSEcCtD
Methylphenidate—Arrhythmia—Dextrothyroxine—hypothyroidism	0.00486	0.00538	CcSEcCtD
Methylphenidate—Arrhythmia—Levothyroxine—hypothyroidism	0.00486	0.00538	CcSEcCtD
Methylphenidate—Bronchitis—Liotrix—hypothyroidism	0.0048	0.00532	CcSEcCtD
Methylphenidate—Alopecia—Dextrothyroxine—hypothyroidism	0.0048	0.00532	CcSEcCtD
Methylphenidate—Alopecia—Levothyroxine—hypothyroidism	0.0048	0.00532	CcSEcCtD
Methylphenidate—Tension—Dextrothyroxine—hypothyroidism	0.00464	0.00514	CcSEcCtD
Methylphenidate—Tension—Levothyroxine—hypothyroidism	0.00464	0.00514	CcSEcCtD
Methylphenidate—Nervousness—Levothyroxine—hypothyroidism	0.0046	0.00509	CcSEcCtD
Methylphenidate—Nervousness—Dextrothyroxine—hypothyroidism	0.0046	0.00509	CcSEcCtD
Methylphenidate—Weight decreased—Liotrix—hypothyroidism	0.00452	0.005	CcSEcCtD
Methylphenidate—SLC6A4—Synaptic Vesicle Pathway—CLTC—hypothyroidism	0.00446	0.0511	CbGpPWpGaD
Methylphenidate—Tremor—Dextrothyroxine—hypothyroidism	0.00443	0.00491	CcSEcCtD
Methylphenidate—Tremor—Levothyroxine—hypothyroidism	0.00443	0.00491	CcSEcCtD
Methylphenidate—Acute coronary syndrome—Liotrix—hypothyroidism	0.00439	0.00486	CcSEcCtD
Methylphenidate—Myocardial infarction—Liotrix—hypothyroidism	0.00437	0.00483	CcSEcCtD
Methylphenidate—Agitation—Dextrothyroxine—hypothyroidism	0.00435	0.00481	CcSEcCtD
Methylphenidate—Agitation—Levothyroxine—hypothyroidism	0.00435	0.00481	CcSEcCtD
Methylphenidate—Angioedema—Levothyroxine—hypothyroidism	0.00432	0.00479	CcSEcCtD
Methylphenidate—Angioedema—Dextrothyroxine—hypothyroidism	0.00432	0.00479	CcSEcCtD
Methylphenidate—Sweating—Liotrix—hypothyroidism	0.00427	0.00473	CcSEcCtD
Methylphenidate—Palpitations—Levothyroxine—hypothyroidism	0.00418	0.00463	CcSEcCtD
Methylphenidate—Palpitations—Dextrothyroxine—hypothyroidism	0.00418	0.00463	CcSEcCtD
Methylphenidate—Convulsion—Dextrothyroxine—hypothyroidism	0.0041	0.00454	CcSEcCtD
Methylphenidate—Convulsion—Levothyroxine—hypothyroidism	0.0041	0.00454	CcSEcCtD
Methylphenidate—Arthralgia—Levothyroxine—hypothyroidism	0.00403	0.00446	CcSEcCtD
Methylphenidate—Arthralgia—Dextrothyroxine—hypothyroidism	0.00403	0.00446	CcSEcCtD
Methylphenidate—Anxiety—Dextrothyroxine—hypothyroidism	0.00402	0.00444	CcSEcCtD
Methylphenidate—Anxiety—Levothyroxine—hypothyroidism	0.00402	0.00444	CcSEcCtD
Methylphenidate—Confusional state—Levothyroxine—hypothyroidism	0.00389	0.00431	CcSEcCtD
Methylphenidate—Confusional state—Dextrothyroxine—hypothyroidism	0.00389	0.00431	CcSEcCtD
Methylphenidate—Shock—Dextrothyroxine—hypothyroidism	0.0038	0.00421	CcSEcCtD
Methylphenidate—Shock—Levothyroxine—hypothyroidism	0.0038	0.00421	CcSEcCtD
Methylphenidate—Tachycardia—Levothyroxine—hypothyroidism	0.00377	0.00417	CcSEcCtD
Methylphenidate—Tachycardia—Dextrothyroxine—hypothyroidism	0.00377	0.00417	CcSEcCtD
Methylphenidate—Hyperhidrosis—Levothyroxine—hypothyroidism	0.00373	0.00413	CcSEcCtD
Methylphenidate—Hyperhidrosis—Dextrothyroxine—hypothyroidism	0.00373	0.00413	CcSEcCtD
Methylphenidate—Flushing—Liotrix—hypothyroidism	0.00371	0.00411	CcSEcCtD
Methylphenidate—Arrhythmia—Liotrix—hypothyroidism	0.00357	0.00395	CcSEcCtD
Methylphenidate—Alopecia—Liotrix—hypothyroidism	0.00353	0.00391	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Dextrothyroxine—hypothyroidism	0.00352	0.0039	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Levothyroxine—hypothyroidism	0.00352	0.0039	CcSEcCtD
Methylphenidate—Insomnia—Dextrothyroxine—hypothyroidism	0.00349	0.00387	CcSEcCtD
Methylphenidate—Insomnia—Levothyroxine—hypothyroidism	0.00349	0.00387	CcSEcCtD
Methylphenidate—Dyspnoea—Dextrothyroxine—hypothyroidism	0.00344	0.00381	CcSEcCtD
Methylphenidate—Dyspnoea—Levothyroxine—hypothyroidism	0.00344	0.00381	CcSEcCtD
Methylphenidate—Tension—Liotrix—hypothyroidism	0.00342	0.00378	CcSEcCtD
Methylphenidate—Nervousness—Liotrix—hypothyroidism	0.00338	0.00374	CcSEcCtD
Methylphenidate—Fatigue—Dextrothyroxine—hypothyroidism	0.00333	0.00369	CcSEcCtD
Methylphenidate—Fatigue—Levothyroxine—hypothyroidism	0.00333	0.00369	CcSEcCtD
Methylphenidate—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC5A7—hypothyroidism	0.00331	0.0379	CbGpPWpGaD
Methylphenidate—Vision blurred—Liotrix—hypothyroidism	0.00328	0.00363	CcSEcCtD
Methylphenidate—Tremor—Liotrix—hypothyroidism	0.00326	0.00361	CcSEcCtD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—DLX2—hypothyroidism	0.00323	0.037	CbGpPWpGaD
Methylphenidate—Agitation—Liotrix—hypothyroidism	0.0032	0.00354	CcSEcCtD
Methylphenidate—Feeling abnormal—Dextrothyroxine—hypothyroidism	0.00318	0.00352	CcSEcCtD
Methylphenidate—Feeling abnormal—Levothyroxine—hypothyroidism	0.00318	0.00352	CcSEcCtD
Methylphenidate—Angioedema—Liotrix—hypothyroidism	0.00318	0.00352	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Levothyroxine—hypothyroidism	0.00316	0.0035	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Dextrothyroxine—hypothyroidism	0.00316	0.0035	CcSEcCtD
Methylphenidate—Syncope—Liotrix—hypothyroidism	0.00312	0.00346	CcSEcCtD
Methylphenidate—Palpitations—Liotrix—hypothyroidism	0.00308	0.00341	CcSEcCtD
Methylphenidate—Urticaria—Dextrothyroxine—hypothyroidism	0.00307	0.0034	CcSEcCtD
Methylphenidate—Urticaria—Levothyroxine—hypothyroidism	0.00307	0.0034	CcSEcCtD
Methylphenidate—Loss of consciousness—Liotrix—hypothyroidism	0.00306	0.00339	CcSEcCtD
Methylphenidate—Body temperature increased—Levothyroxine—hypothyroidism	0.00305	0.00338	CcSEcCtD
Methylphenidate—Abdominal pain—Dextrothyroxine—hypothyroidism	0.00305	0.00338	CcSEcCtD
Methylphenidate—Body temperature increased—Dextrothyroxine—hypothyroidism	0.00305	0.00338	CcSEcCtD
Methylphenidate—Abdominal pain—Levothyroxine—hypothyroidism	0.00305	0.00338	CcSEcCtD
Methylphenidate—Convulsion—Liotrix—hypothyroidism	0.00302	0.00334	CcSEcCtD
Methylphenidate—Hypertension—Liotrix—hypothyroidism	0.00301	0.00333	CcSEcCtD
Methylphenidate—Chest pain—Liotrix—hypothyroidism	0.00296	0.00328	CcSEcCtD
Methylphenidate—Arthralgia—Liotrix—hypothyroidism	0.00296	0.00328	CcSEcCtD
Methylphenidate—Anxiety—Liotrix—hypothyroidism	0.00295	0.00327	CcSEcCtD
Methylphenidate—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC5A7—hypothyroidism	0.00293	0.0336	CbGpPWpGaD
Methylphenidate—Confusional state—Liotrix—hypothyroidism	0.00286	0.00317	CcSEcCtD
Methylphenidate—Oedema—Liotrix—hypothyroidism	0.00284	0.00314	CcSEcCtD
Methylphenidate—Anaphylactic shock—Liotrix—hypothyroidism	0.00284	0.00314	CcSEcCtD
Methylphenidate—Infection—Liotrix—hypothyroidism	0.00282	0.00312	CcSEcCtD
Methylphenidate—Shock—Liotrix—hypothyroidism	0.0028	0.00309	CcSEcCtD
Methylphenidate—SLC6A4—NRF2 pathway—SLC5A7—hypothyroidism	0.00277	0.0318	CbGpPWpGaD
Methylphenidate—Tachycardia—Liotrix—hypothyroidism	0.00277	0.00307	CcSEcCtD
Methylphenidate—Asthenia—Dextrothyroxine—hypothyroidism	0.00277	0.00307	CcSEcCtD
Methylphenidate—Asthenia—Levothyroxine—hypothyroidism	0.00277	0.00307	CcSEcCtD
Methylphenidate—Hyperhidrosis—Liotrix—hypothyroidism	0.00275	0.00304	CcSEcCtD
Methylphenidate—Pruritus—Levothyroxine—hypothyroidism	0.00273	0.00302	CcSEcCtD
Methylphenidate—Pruritus—Dextrothyroxine—hypothyroidism	0.00273	0.00302	CcSEcCtD
Methylphenidate—Anorexia—Liotrix—hypothyroidism	0.00271	0.003	CcSEcCtD
Methylphenidate—Diarrhoea—Levothyroxine—hypothyroidism	0.00264	0.00293	CcSEcCtD
Methylphenidate—Diarrhoea—Dextrothyroxine—hypothyroidism	0.00264	0.00293	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Liotrix—hypothyroidism	0.00259	0.00287	CcSEcCtD
Methylphenidate—Insomnia—Liotrix—hypothyroidism	0.00257	0.00284	CcSEcCtD
Methylphenidate—Paraesthesia—Liotrix—hypothyroidism	0.00255	0.00282	CcSEcCtD
Methylphenidate—Dyspnoea—Liotrix—hypothyroidism	0.00253	0.0028	CcSEcCtD
Methylphenidate—Decreased appetite—Liotrix—hypothyroidism	0.00247	0.00273	CcSEcCtD
Methylphenidate—Vomiting—Dextrothyroxine—hypothyroidism	0.00246	0.00272	CcSEcCtD
Methylphenidate—Vomiting—Levothyroxine—hypothyroidism	0.00246	0.00272	CcSEcCtD
Methylphenidate—Fatigue—Liotrix—hypothyroidism	0.00245	0.00271	CcSEcCtD
Methylphenidate—Rash—Dextrothyroxine—hypothyroidism	0.00244	0.0027	CcSEcCtD
Methylphenidate—Rash—Levothyroxine—hypothyroidism	0.00244	0.0027	CcSEcCtD
Methylphenidate—Dermatitis—Dextrothyroxine—hypothyroidism	0.00243	0.00269	CcSEcCtD
Methylphenidate—Dermatitis—Levothyroxine—hypothyroidism	0.00243	0.00269	CcSEcCtD
Methylphenidate—Constipation—Liotrix—hypothyroidism	0.00243	0.00269	CcSEcCtD
Methylphenidate—Headache—Levothyroxine—hypothyroidism	0.00242	0.00268	CcSEcCtD
Methylphenidate—Headache—Dextrothyroxine—hypothyroidism	0.00242	0.00268	CcSEcCtD
Methylphenidate—SLC6A2—NRF2 pathway—SLC5A7—hypothyroidism	0.00239	0.0273	CbGpPWpGaD
Methylphenidate—Feeling abnormal—Liotrix—hypothyroidism	0.00234	0.00259	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Liotrix—hypothyroidism	0.00232	0.00257	CcSEcCtD
Methylphenidate—Nausea—Dextrothyroxine—hypothyroidism	0.00229	0.00254	CcSEcCtD
Methylphenidate—Nausea—Levothyroxine—hypothyroidism	0.00229	0.00254	CcSEcCtD
Methylphenidate—Urticaria—Liotrix—hypothyroidism	0.00226	0.0025	CcSEcCtD
Methylphenidate—Abdominal pain—Liotrix—hypothyroidism	0.00225	0.00249	CcSEcCtD
Methylphenidate—Body temperature increased—Liotrix—hypothyroidism	0.00225	0.00249	CcSEcCtD
Methylphenidate—SLC6A3—nerve—hypothyroidism	0.00213	0.231	CbGeAlD
Methylphenidate—SLC6A3—NRF2 pathway—SLC5A7—hypothyroidism	0.00211	0.0242	CbGpPWpGaD
Methylphenidate—Hypersensitivity—Liotrix—hypothyroidism	0.00209	0.00232	CcSEcCtD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—THRB—hypothyroidism	0.00208	0.0238	CbGpPWpGaD
Methylphenidate—Asthenia—Liotrix—hypothyroidism	0.00204	0.00226	CcSEcCtD
Methylphenidate—Pruritus—Liotrix—hypothyroidism	0.00201	0.00222	CcSEcCtD
Methylphenidate—Diarrhoea—Liotrix—hypothyroidism	0.00194	0.00215	CcSEcCtD
Methylphenidate—Dizziness—Liotrix—hypothyroidism	0.00188	0.00208	CcSEcCtD
Methylphenidate—Vomiting—Liotrix—hypothyroidism	0.00181	0.002	CcSEcCtD
Methylphenidate—Rash—Liotrix—hypothyroidism	0.00179	0.00198	CcSEcCtD
Methylphenidate—Dermatitis—Liotrix—hypothyroidism	0.00179	0.00198	CcSEcCtD
Methylphenidate—SLC6A4—Circadian rythm related genes—NKX2-1—hypothyroidism	0.00178	0.0204	CbGpPWpGaD
Methylphenidate—Headache—Liotrix—hypothyroidism	0.00178	0.00197	CcSEcCtD
Methylphenidate—SLC6A2—nerve—hypothyroidism	0.00172	0.186	CbGeAlD
Methylphenidate—Nausea—Liotrix—hypothyroidism	0.00169	0.00187	CcSEcCtD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—SLC5A7—hypothyroidism	0.00164	0.0188	CbGpPWpGaD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—SLC5A7—hypothyroidism	0.0015	0.0172	CbGpPWpGaD
Methylphenidate—CYP2D6—urine—hypothyroidism	0.00136	0.148	CbGeAlD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—SLC5A7—hypothyroidism	0.00133	0.0153	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—SLC5A7—hypothyroidism	0.00126	0.0144	CbGpPWpGaD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—SLC26A4—hypothyroidism	0.00125	0.0143	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—SLC5A5—hypothyroidism	0.00111	0.0127	CbGpPWpGaD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—SLC26A4—hypothyroidism	0.0011	0.0126	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—NEFL—hypothyroidism	0.00106	0.0121	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—SLC5A5—hypothyroidism	0.000954	0.0109	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—SLC5A5—hypothyroidism	0.000845	0.00967	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—AVP—hypothyroidism	0.000828	0.00948	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—NEFL—hypothyroidism	0.000811	0.00929	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	0.000764	0.00875	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	0.000677	0.00775	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—AVP—hypothyroidism	0.000676	0.00774	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	0.000633	0.00725	CbGpPWpGaD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—SLC5A5—hypothyroidism	0.000601	0.00688	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	0.000561	0.00642	CbGpPWpGaD
Methylphenidate—SLC6A2—gonad—hypothyroidism	0.000546	0.0592	CbGeAlD
Methylphenidate—SLC6A4—blood—hypothyroidism	0.000541	0.0586	CbGeAlD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—SLC5A5—hypothyroidism	0.000532	0.0061	CbGpPWpGaD
Methylphenidate—SLC6A3—testis—hypothyroidism	0.000488	0.0529	CbGeAlD
Methylphenidate—SLC6A2—adrenal gland—hypothyroidism	0.000476	0.0516	CbGeAlD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—AVP—hypothyroidism	0.000473	0.00542	CbGpPWpGaD
Methylphenidate—SLC6A3—cerebellum—hypothyroidism	0.000451	0.0488	CbGeAlD
Methylphenidate—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	0.000422	0.00483	CbGpPWpGaD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—AVP—hypothyroidism	0.000419	0.0048	CbGpPWpGaD
Methylphenidate—SLC6A2—testis—hypothyroidism	0.000394	0.0427	CbGeAlD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	0.000342	0.00391	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	0.000305	0.0035	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	0.000271	0.0031	CbGpPWpGaD
Methylphenidate—CYP2D6—blood—hypothyroidism	0.000261	0.0282	CbGeAlD
Methylphenidate—CYP2D6—female gonad—hypothyroidism	0.000243	0.0263	CbGeAlD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—AVP—hypothyroidism	0.00024	0.00275	CbGpPWpGaD
Methylphenidate—CYP2D6—testis—hypothyroidism	0.000216	0.0234	CbGeAlD
Methylphenidate—CYP2D6—Metabolism—IYD—hypothyroidism	0.000214	0.00245	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—AVP—hypothyroidism	0.000213	0.00244	CbGpPWpGaD
Methylphenidate—CYP2D6—liver—hypothyroidism	0.000204	0.0221	CbGeAlD
Methylphenidate—CYP2D6—cerebellum—hypothyroidism	0.000199	0.0216	CbGeAlD
Methylphenidate—CYP2D6—Metabolism—ATP5O—hypothyroidism	0.000182	0.00209	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—POMC—hypothyroidism	0.000182	0.00208	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—TPO—hypothyroidism	0.000171	0.00196	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—TSHB—hypothyroidism	7.93e-05	0.000908	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PIK3C2A—hypothyroidism	7.07e-05	0.000809	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—SLC5A5—hypothyroidism	5.94e-05	0.00068	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—POMC—hypothyroidism	3.11e-05	0.000356	CbGpPWpGaD
